W H Frishman

Summary

Affiliation: New York Medical College
Country: USA

Publications

  1. ncbi request reprint Drug therapies for mesenteric vascular disease
    Hossein Tabriziani
    Department of Medicine, St Barnabas Hospital Center, Bronx, New York, USA
    Heart Dis 4:306-14. 2002
  2. ncbi request reprint Aldosterone and aldosterone antagonism in systemic hypertension
    William H Frishman
    Department of Medicine, New York Medical College, Munger Pavilion 263, Valhalla, NY 10595, USA
    Curr Hypertens Rep 6:195-200. 2004
  3. ncbi request reprint Nicotine and non-nicotine smoking cessation pharmacotherapies
    William H Frishman
    Department of Medicine, New York Medical College Westchester Medical Center, Valhalla, New York 10595, USA
    Cardiol Rev 14:57-73. 2006
  4. ncbi request reprint Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease
    Gautham Ravipati
    Division of General Internal Medicine, New York Medical College Westchester Medical Center, Valhalla, New York 10595, USA
    Cardiol Rev 15:76-86. 2007
  5. ncbi request reprint Antihypertensive properties of a high-dose combination of trandolapril and verapamil-SR
    Franz Messerli
    Department of Medicine, Division of Cardiology, St Luke s Roosevelt Hospital and Columbia University, New York, NY, USA
    Blood Press Suppl 1:6-9. 2007
  6. doi request reprint The role of nonpharmacologic device interventions in the management of drug-resistant hypertension
    William H Frishman
    Department of Medicine, New York Medical College, Valhalla, NY, 10595, USA
    Curr Atheroscler Rep 16:405. 2014
  7. doi request reprint β-Adrenergic blockade in cardiovascular disease
    William H Frishman
    Department of Medicine, New York Medical College Westchester Medical Center, Valhalla, NY 10595, USA
    J Cardiovasc Pharmacol Ther 18:310-9. 2013
  8. doi request reprint Vascular and heart diseases in the incumbent presidents and vice presidents of the United States of america: a medical-historical perspective
    William H Frishman
    Department of Medicine, New York Medical College Westchester Medical Center, Valhalla, NY 10595, USA
    Cardiol Rev 21:1-8. 2013
  9. doi request reprint Pharmacology of antiarrhythmic drugs in elderly patients
    William H Frishman
    Department of Medicine, New York Medical College, Westchester Medical Center, Valhalla, NY 10595, USA
    Clin Geriatr Med 28:575-615. 2012
  10. doi request reprint Cardiovascular drugs in pregnancy
    William H Frishman
    Department of Medicine, New York Medical College Westchester Medical Center, Munger Pavilion, Room 263, Valhalla, NY 10595, USA
    Cardiol Clin 30:463-91. 2012

Collaborators

Detail Information

Publications99

  1. ncbi request reprint Drug therapies for mesenteric vascular disease
    Hossein Tabriziani
    Department of Medicine, St Barnabas Hospital Center, Bronx, New York, USA
    Heart Dis 4:306-14. 2002
    ..This article outlines the appropriate medical management of ischemic disorders of the intestine, with an emphasis on the drug treatments presently used in clinical practice and those being studied in the laboratory...
  2. ncbi request reprint Aldosterone and aldosterone antagonism in systemic hypertension
    William H Frishman
    Department of Medicine, New York Medical College, Munger Pavilion 263, Valhalla, NY 10595, USA
    Curr Hypertens Rep 6:195-200. 2004
    ..Hyperkalemia remains a potential problem with all aldosterone antagonists...
  3. ncbi request reprint Nicotine and non-nicotine smoking cessation pharmacotherapies
    William H Frishman
    Department of Medicine, New York Medical College Westchester Medical Center, Valhalla, New York 10595, USA
    Cardiol Rev 14:57-73. 2006
    ..Various approaches under investigation include the use of partial nicotine agonists (eg, varenicline), inhibitors of the hepatic P-450 enzyme (eg, methoxsalen), cannaboid-1 receptor antagonists (eg, rimonabant), and nicotine vaccines...
  4. ncbi request reprint Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease
    Gautham Ravipati
    Division of General Internal Medicine, New York Medical College Westchester Medical Center, Valhalla, New York 10595, USA
    Cardiol Rev 15:76-86. 2007
    ..The drug will be marketed under the trade name of Revatio, not Viagra, the name used for the ED indication. The approved dose for primary pulmonary hypertension is 20 mg 3 times daily...
  5. ncbi request reprint Antihypertensive properties of a high-dose combination of trandolapril and verapamil-SR
    Franz Messerli
    Department of Medicine, Division of Cardiology, St Luke s Roosevelt Hospital and Columbia University, New York, NY, USA
    Blood Press Suppl 1:6-9. 2007
    ..Despite differences in the risk profiles of previously studied patients and INVEST patients, the antihypertensive effects of Ve+Tr were similar...
  6. doi request reprint The role of nonpharmacologic device interventions in the management of drug-resistant hypertension
    William H Frishman
    Department of Medicine, New York Medical College, Valhalla, NY, 10595, USA
    Curr Atheroscler Rep 16:405. 2014
    ..Both carotid sinus stimulation and renal denervation are now being evaluated in clinical trials for the long-term control of hypertension. ..
  7. doi request reprint β-Adrenergic blockade in cardiovascular disease
    William H Frishman
    Department of Medicine, New York Medical College Westchester Medical Center, Valhalla, NY 10595, USA
    J Cardiovasc Pharmacol Ther 18:310-9. 2013
    ..In addition, long-acting and ultra-short-acting formulations of β-blockers have also demonstrated a remarkable record of clinical safety in patients of all ages...
  8. doi request reprint Vascular and heart diseases in the incumbent presidents and vice presidents of the United States of america: a medical-historical perspective
    William H Frishman
    Department of Medicine, New York Medical College Westchester Medical Center, Valhalla, NY 10595, USA
    Cardiol Rev 21:1-8. 2013
    ..A discussion of how atrial fibrillation has affected the Presidents is also included...
  9. doi request reprint Pharmacology of antiarrhythmic drugs in elderly patients
    William H Frishman
    Department of Medicine, New York Medical College, Westchester Medical Center, Valhalla, NY 10595, USA
    Clin Geriatr Med 28:575-615. 2012
    ..Despite the large number of antiarrhythmic drugs having different electrophysiologic actions, as described in this article, only the β-blockers have been shown to be effective in reducing mortality and to lack proarrhythmic actions...
  10. doi request reprint Cardiovascular drugs in pregnancy
    William H Frishman
    Department of Medicine, New York Medical College Westchester Medical Center, Munger Pavilion, Room 263, Valhalla, NY 10595, USA
    Cardiol Clin 30:463-91. 2012
    ..Many drugs are also transferred into human milk with potential adverse effects on the nursing infant. This article summarizes some of the literature concerning the risks and benefits of using cardiovascular drugs during pregnancy...
  11. doi request reprint Cardiovascular pharmacologic therapies under investigation: 2012
    William H Frishman
    Departments of Medicine, New York Medical College Westchester Medical Center, Valhalla, NY 10595, USA
    Cardiol Rev 20:102-10. 2012
    ..Intensive efforts over the past 45 years to develop important pharmacologic treatments have reduced CV risk dramatically. Described in this article are over 150 drugs being developed to prevent and treat CV disease...
  12. ncbi request reprint Pathophysiology, diagnosis, and treatment of orthostatic hypotension and vasovagal syncope
    Marvin S Medow
    Department of Pediatrics, New York Medical College, Valhalla, New York 10595, USA
    Cardiol Rev 16:4-20. 2008
    ..Treatment for recurrent vasovagal syncope includes increased salt and water intake and various drug treatments, most of which are still under investigation...
  13. doi request reprint β-Adrenergic blockers
    William H Frishman
    Department of Medicine, New York Medical College Westchester Medical Center, Valhalla, NY, USA
    J Clin Hypertens (Greenwich) 13:649-53. 2011
    ....
  14. doi request reprint beta-Adrenergic blockers: a 50-year historical perspective
    William H Frishman
    Department of Medicine, New York Medical College, Westchester Medical Center, Valhalla, NY, USA
    Am J Ther 15:565-76. 2008
    ..Indeed, the beta-adrenergic blockers have provided us with a great clinical legacy for now and in years to come...
  15. pmc Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction
    William H Frishman
    Departments of Medicine and Pharmacology, New York Medical College Westchester Medical Center, Valhalla, NY 10595, USA
    Vasc Health Risk Manag 4:1387-400. 2008
    ..This review presents an overview of the clinical and pharmacologic carvedilol controlled-release data...
  16. ncbi request reprint Pathophysiology and medical management of systemic hypertension in preeclampsia
    William H Frishman
    Department of Medicine, New York Medical College, Valhalla, NY 10595, USA
    Curr Hypertens Rep 8:502-11. 2006
    ....
  17. ncbi request reprint Drug treatment of orthostatic hypotension and vasovagal syncope
    William H Frishman
    Department of Medicine, New York Medical College Westchester Medical Center, Valhalla, New York 10595, USA
    Heart Dis 5:49-64. 2003
    ..Treatment for recurrent vasovagal syncope includes increased salt intake, and various drug treatments, most of which are still under investigation...
  18. ncbi request reprint Are antihypertensive agents protective against dementia? A review of clinical and preclinical data
    William H Frishman
    Department of Medicine, New York Medical College, Westchester Medical Center, Valhalla, New York 10595, USA
    Heart Dis 4:380-6. 2002
    ..In animal models, these newer agents also have been shown to prevent the progression of hypertensive microvascular damage. Their neuroprotective effects offer possible unique advantages in the management of hypertension...
  19. ncbi request reprint Smoking cessation pharmacotherapy--nicotine and non-nicotine preparations
    William H Frishman
    Department of Medicine, New York Medical College Westchester Medical Center, Valhalla, NY 10595, USA
    Prev Cardiol 10:10-22. 2007
    ..A novel approach to treatment using the cannabinoid-1 receptor antagonist rimonabant is also under investigation...
  20. ncbi request reprint An odyssey of a clinical researcher
    William H Frishman
    Department of Medicine, New York Medical College, Westchester Medical Center, Valhalla, New York 10595, USA
    Heart Dis 4:392-6. 2002
  21. ncbi request reprint Increased vascular compliance/decreased cardiovascular risk: what the studies tell us
    W H Frishman
    Department of Medicine, Munger Pavilion, Room 263, New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USA
    Heart Dis 2:384-8. 2000
    ..ACE inhibitors restore endothelial cell balance to improve arterial compliance, thus they can provide benefits beyond lowering blood pressure...
  22. ncbi request reprint Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease
    William H Frishman
    Department of Medicine, New York Medical College, Munger Pavillion 263, Valhalla, NY 10595, USA
    Expert Rev Cardiovasc Ther 2:675-81. 2004
    ..Amlodipine/atorvastatin retains the safety and efficacy of its parent compounds whilst simplifying the management of these comorbid conditions, in what may be considered the first version of a polypill...
  23. doi request reprint Pharmacologic management of mesenteric occlusive disease
    William H Frishman
    Department of Medicine, New York Medical College Westchester Medical Center, Valhalla, New York 10595, USA
    Cardiol Rev 16:59-68. 2008
    ..This article outlines the appropriate pharmacologic management of ischemic disorders of the intestine, with an emphasis on the pharmacologic treatments presently being used in clinical practice and those being studied in the laboratory...
  24. ncbi request reprint Cholesteryl ester transfer protein inhibition for coronary heart disease prevention: real hope or despair?
    William H Frishman
    Department of Medicine, New York Medical College Westchester Medical Center, Valhalla, NY, USA
    Am J Med 121:644-6. 2008
  25. doi request reprint Smoking cessation pharmacotherapy
    William H Frishman
    Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY, USA
    Ther Adv Cardiovasc Dis 3:287-308. 2009
    ..g. mecamylamine) and glucose tablets. Various approaches under investigation include inhibitors of the hepatic P450 enzyme (e.g. methoxsalen), cannabinoid-1 receptor antagonists (e.g. rimonabant), and nicotine vaccines...
  26. ncbi request reprint Importance of medication adherence in cardiovascular disease and the value of once-daily treatment regimens
    William H Frishman
    Department of Medicine, New York Medical College Westchester Medical Center, Valhalla, New York 10595, USA
    Cardiol Rev 15:257-63. 2007
    ..This review will discuss the impact of adherence to prescribed therapies for CVD, outline common barriers to adherence, and demonstrate the value of once-daily dosing regimens for improved patient adherence...
  27. doi request reprint Statin-drug interactions: not a class effect
    William H Frishman
    Department of Medicine, New York Medical College Westchester Medical Center, Valhalla, New York 10595, USA
    Cardiol Rev 16:205-12. 2008
    ..Careful consideration of the lipid lowering efficacy and also the risk profile for drug-drug interactions should be taken before initiating patients on statin therapy, or switching patients between different drugs of the statin class...
  28. ncbi request reprint Tobacco smoking, nicotine, and nicotine and non-nicotine replacement therapies
    W H Frishman
    Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, NY 10595, USA
    Heart Dis 3:365-77. 2001
    ..Nicotine replacement and nonnicotine modalities have been used alone and in combination to help in smoking cessation. These treatment modalities appear to be safe in patients with known stable coronary artery disease...
  29. ncbi request reprint Serotonin and the heart
    W H Frishman
    Department of Medicine, New York Medical College, Valhalla 10595, USA
    Ann Med 32:195-209. 2000
    ..Prolongation of the ECG QT interval with 5-HT2 serotonergic receptor blockers may pose a potential risk with these treatments in some patients...
  30. ncbi request reprint Pathophysiology and medical management of systemic hypertension and pre-eclampsia in pregnancy
    W H Frishman
    Department of Medicine, New York Medical College, Westchester Medical Center, Valhalla, NY 10595, USA
    Minerva Med 97:347-64. 2006
    ....
  31. ncbi request reprint Cardiovascular drug therapy in the elderly
    Wilbert S Aronow
    Department of Medicine, New York Medical College Westchester Medical Center, Valhalla, New York 10595, USA
    Cardiol Rev 15:195-215. 2007
    ..This article also discusses the adverse effects of cardiovascular drugs in the elderly, medications best to avoid in the elderly, and the prudent use of medications in the elderly...
  32. doi request reprint Angiotensin receptor blockers for management of hypertension
    Daniel F Catanzaro
    Department of Medicine, SUNY, Brooklyn, NY 10203, USA
    South Med J 103:669-73. 2010
    ..The combination of clinical efficacy and tolerability should render ARBs as a major treatment alternative for hypertension...
  33. ncbi request reprint Gender, ethnicity, and genes in cardiovascular disease. Part 2: implications for pharmacotherapy
    Benjamin M Schaefer
    Department of Medicine, Jacobi Medical Center Albert Einstein College of Medicine, Bronx, NY, USA
    Heart Dis 5:202-14. 2003
    ..Torsades de Pointes is more common in women related to a longer QT-interval. Lower dose OCPs decrease the risk of MI, stroke and thrombosis. HRTs are not effective for CAD prevention...
  34. ncbi request reprint Cardiovascular considerations in using topical, oral, and intravenous drugs for the treatment of glaucoma and ocular hypertension: focus on beta-adrenergic blockade
    W H Frishman
    Departments of Medicine, New York Medical College Westchester Medical Center, Valhalla, New York 10595, USA
    Heart Dis 3:386-97. 2001
    ..The systemic toxicity of these agents is reviewed, along with the possible drug interactions. Brief mention is also made of other antiglaucoma medications used alone and in combination with topical beta-blockers...
  35. ncbi request reprint A factorial study of combination hypertension treatment with metoprolol succinate extended release and felodipine extended release results of the Metoprolol Succinate-Felodipine Antihypertension Combination Trial (M-FACT)
    William H Frishman
    Department of Medicine and Pharmacology, New York Medical College, Valhalla, New York 10595, USA
    Am J Hypertens 19:388-95. 2006
    ..beta-Blockers and dihydropyridine calcium channel blockers are effective as monotherapy in hypertensive patients and have complementary mechanisms for lowering BP...
  36. ncbi request reprint Calcium channel blockers: differences between subclasses
    William H Frishman
    Department of Medicine, New York Medical College, Valhalla, New York 10595, USA
    Am J Cardiovasc Drugs 7:17-23. 2007
    ..Representatives of both classes are now available in fixed-dose combinations containing an ACE inhibitor, the benefits of which include effective 24-hour BP control, a reduced incidence of adverse effects, and improved adherence...
  37. ncbi request reprint Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema
    William H Frishman
    Department of Medicine, New York Medical College, Valhalla, New York 10595, USA
    Am J Cardiol 89:18D-25D. 2002
    ..Patients at risk for hypertension should be monitored for changes in blood pressure during NSAID treatment...
  38. ncbi request reprint Innovative drug treatments for viral and autoimmune myocarditis
    William H Frishman
    Department of Medicine and Pharmacology, New York Medical College, Valhalla, NY 10595, USA
    Heart Dis 4:171-83. 2002
    ..Additionally, better means need to be established for distinguishing between viral and noninfectious autoimmune forms of the disease, so that appropriate treatment can be instituted...
  39. doi request reprint U.S. medical students' perceptions of the adequacy of their schools' curricular attention to care at the end of life: 1998-2006
    Daniel P Sulmasy
    The John J Conley Department of Ethics, St Vincent s Hospital, New York, New York 10011, USA
    J Palliat Med 11:707-16. 2008
    ..Little is known about the long-term effectiveness of recent efforts to improve end-of-life care education at U.S. medical schools...
  40. doi request reprint Targeting heme oxygenase: therapeutic implications for diseases of the cardiovascular system
    Stephen J Peterson
    Department of Medicine, New York Medical College Westchester Medical Center, Valhalla, New York, USA
    Cardiol Rev 17:99-111. 2009
    ....
  41. doi request reprint Testosterone and coronary artery disease
    Monica D Schwarcz
    Department of Medicine, New York Medical College Westchester Medical Center, Valhalla, NY 10595, USA
    Cardiol Rev 18:251-7. 2010
    ..The role of testosterone in male cardiovascular health is not completely understood, and additional studies are needed to explain its effect on atherosclerosis and its complications...
  42. ncbi request reprint Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (Inspra)
    Charles T Stier
    Department of Pharmacology, New York Medical College, Valhalla, NY 10595, USA
    Heart Dis 5:102-18. 2003
    ..Eplerenone has already been approved for the treatment of systemic hypertension, and several clinical trials are currently underway to identify other therapeutic uses for this agent in cardiovascular disease management...
  43. ncbi request reprint Antihypertensive properties of a high-dose combination of trandolapril and verapamil-SR
    Franz Messerli
    Department of Medicine, Division of Cardiology, St Luke s Roosevelt Hospital and Columbia University, New York, NY, USA
    Blood Press Suppl 16:6-9. 2007
    ..Despite differences in the risk profiles of previously studied patients and INVEST patients, the antihypertensive effects of Ve+Tr were similar...
  44. ncbi request reprint Serum creatinine and blood urea nitrogen over a six-year period in the very old. Creatinine and BUN in the very old
    D A Feinfeld
    Department of Medicine, Nassau County Medical Center, East Meadow, New York, USA
    Geriatr Nephrol Urol 8:131-5. 1998
    ..Use of diuretics and NSAID by functioning elderly individuals is not necessarily associated with worsening azotemia...
  45. doi request reprint Flavanol-rich cocoa: a cardioprotective nutraceutical
    Ramona Mehrinfar
    Department of Medicine, Harbor UCLA Medical Center, Los Angeles, California, USA
    Cardiol Rev 16:109-15. 2008
    ..This review discusses the cardioprotective properties of flavanols, and the mechanisms underlying these beneficial actions...
  46. ncbi request reprint Variability of response to clopidogrel: possible mechanisms and clinical implications
    Theresa Nguyen
    Department of Medicine, Virginia Mason Medical Center, Seattle, Washington, USA
    Cardiol Rev 14:136-42. 2006
    ..The best laboratory procedure to screen for possible clopidogrel variability of response remains to be determined...
  47. ncbi request reprint Pathophysiology and medical management of systemic hypertension in pregnancy
    William H Frishman
    Department of Medicine and, New York Medical College Westchester Medical Center, Valhalla, NY 10595, USA
    Cardiol Rev 13:274-84. 2005
    ....
  48. ncbi request reprint Exercise as a treatment modality for congestive heart failure
    Travis Monchamp
    Department of Medicine, University of California Los Angeles Medical Center, Los Angeles, California, USA
    Heart Dis 4:110-6. 2002
    ..This article reviews the current experience with exercise and congestive heart failure and discusses strategies used to implement an exercise program for patients...
  49. ncbi request reprint Pharmacotherapy of diabetes mellitus: implications for the prevention and treatment of cardiovascular disease
    Enzo Ragucci
    Department of Medicine, The Albert Einstein College of Medicine Montefiore Medical Center, Bronx, New York 10461 2373, USA
    Heart Dis 5:18-33. 2003
    ..Various strategies to improve outcomes include the use of tight blood glucose control, and various coronary interventions are currently under clinical study...
  50. ncbi request reprint Treatment of hypertension and prevention of ischemic stroke
    Wilbert S Aronow
    Department of Medicine, New York Medical College, Munger Pavilion, Room 263, Valhalla, NY 10595, USA
    Curr Cardiol Rep 6:124-9. 2004
    ..The overall data also suggest that reduction of stroke in persons with hypertension is related more to a reduction in blood pressure than to the type of antihypertensive drugs used...
  51. ncbi request reprint Endothelin and endothelin antagonism: roles in cardiovascular health and disease
    P Tamirisa
    Department of Medicine, Albert Einstein College of Medicine Montefiore Medical Center, Bronx, NY 10461, USA
    Am Heart J 130:601-10. 1995
    ..The endothelin antagonists have great potential as agents for use in the treatment of a wide spectrum of disease entities and as biologic probes for understanding the actions of endothelin in human beings...
  52. ncbi request reprint Antioxidant vitamins and enzymatic and synthetic oxygen-derived free radical scavengers in the prevention and treatment of cardiovascular disease
    D U Nayak
    Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, New York, USA
    Heart Dis 3:28-45. 2001
    ..In this article, the pathogenesis of free radical production and cell injury are discussed, and therapeutic approaches for disease prevention are presented...
  53. ncbi request reprint Cardiovascular considerations with anthracycline use in patients with cancer
    M A Nelson
    Department of Medicine, The Albert Einstein College of Medicine, Bronx, New York, USA
    Heart Dis 3:157-68. 2001
    ..Other strategies that have been evaluated are dietary glutamine supplementation and the use of the antioxidant probucol...
  54. ncbi request reprint Inhibition of myocardial apoptosis as a therapeutic target in cardiovascular disease prevention: focus on caspase inhibition
    N Guttenplan
    Department of Medicine, New York Medical College/Westchester Medical Center, Valhalla, New York 10595, USA
    Heart Dis 3:313-8. 2001
    ..In addition, apoptosis in the region bordering the infarct can influence the development of ischemic cardiomyopathy and ventricular dilation...
  55. ncbi request reprint Ticlopidine-associated thrombotic thrombocytopenic purpura
    N Naseer
    Divisions of General Internal Medicine, New York Medical College/Westchester Medical Center, Valhalla, New York 10595, USA
    Heart Dis 3:221-3. 2001
    ..The patient responded successfully to plasmapheresis. The authors are reporting this case to emphasize the unpredictable nature of the association between the drug and the disease, which necessitates careful hematologic monitoring...
  56. ncbi request reprint Endothelin as a therapeutic target in the treatment of cardiovascular disease
    S Kaur
    Division of General Internal Medicine, New York Medical College/Westchester Medical Center, Valhalla 10595, USA
    Heart Dis 3:176-88. 2001
    ..Based on the promising results from animal studies, active research and drug development programs are under way to investigate the clinical potential of endothelin antagonism for treatment of cardiovascular disease...
  57. ncbi request reprint Congestive heart failure and continuous positive airway pressure therapy: support of a new modality for improving the prognosis and survival of patients with advanced congestive heart failure
    Gary T Midelton
    Department of Medicine, New York Medical College, Valhalla, New York 10595, USA
    Heart Dis 4:102-9. 2002
    ..Other benefits include improvement in New York Heart Association functional class status and improvement in dyspnea...
  58. doi request reprint Effect of beta blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and statins on mortality in patients with implantable cardioverter-defibrillators
    Hoang M Lai
    Department of Medicine, Cardiology Division, New York Medical College, Valhalla, NY, USA
    Am J Cardiol 102:77-8. 2008
    ..In conclusion, patients with implantable cardioverter-defibrillators should be treated with beta blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and statins to reduce mortality...
  59. ncbi request reprint Beta-adrenergic blockers in systemic hypertension: pharmacokinetic considerations related to the current guidelines
    William H Frishman
    Department of Medicine, New York Medical College Westchester Medical Center, Room 263 Munger Pavilion, Valhalla, NY 10595, USA
    Clin Pharmacokinet 41:505-16. 2002
    ..Despite the pharmacokinetic differences among beta-blockers, these drugs should always be titrated to achieve the desired individual patient response...
  60. ncbi request reprint Contrast-associated nephropathy
    Vikas R Soma
    Department of Medicine, Bronx VA Medical Center, Bronx, New York, USA
    Heart Dis 4:372-9. 2002
    ..The growing use of these new agents, such as acetylcysteine, endothelin blockers, and most recently fenoldopam, has increased the options available for the prevention of CaN...
  61. ncbi request reprint Neuropsychiatric effects of cardiovascular drug therapy
    Seth Keller
    Department of Medicine, Division of Cardiology, Beth Israel Medical Center, New York, New York 10595, USA
    Cardiol Rev 11:73-93. 2003
    ..Since neuropsychiatric symptoms are seen in patients with cardiovascular disease, clinicians should be aware of the possible relationship between these symptoms and concurrent cardiovascular drug therapy...
  62. doi request reprint Statins reduce appropriate cardioverter-defibrillator shocks and mortality in patients with heart failure and combined cardiac resynchronization and implantable cardioverter-defibrillator therapy
    Harit Desai
    Department of Medicine, New York Medical College, Valhalla, 10595, USA
    J Cardiovasc Pharmacol Ther 14:176-9. 2009
    ..05), use of digoxin (risk ratio = 4.2), systemic hypertension (risk ratio = 14.2), diabetes (risk ratio = 4.3), and left ventricular ejection fraction (risk ratio = 1.1)...
  63. ncbi request reprint Aspirin resistance: mechanisms and clinical implications
    Costas Hanjis
    Department of Medicine, Albert Einstein College of Medicine Montefiore Medical Center, Bronx, New York, USA
    Cardiol Rev 14:18-25. 2006
    ..Those individuals at high risk for aspirin resistance might best be treated with an additional oral antiplatelet drug (eg, clopidogrel) to achieve maximal protection against arterial thrombotic events...
  64. ncbi request reprint Sauna as a therapeutic option for cardiovascular disease
    Yen Nguyen
    Department of Medicine, Stanford Medical School Santa Clara Valley Medical Center, San Jose, CA, USA
    Cardiol Rev 12:321-4. 2004
    ..The data reported to date have been promising, but definitive studies are not possible because sauna treatment would be difficult to evaluate in a double-blind, placebo-controlled study...
  65. doi request reprint Cardiovascular and respiratory considerations with pharmacotherapy of glaucoma and ocular hypertension
    Jung A Han
    Department of Medicine, Mt Vernon Hospital, Mt Vernon, New York, USA
    Cardiol Rev 16:95-108. 2008
    ..Mention is made of other antiglaucoma medications used alone and in combination with topical beta-blockers. Identification of genetic loci-a bold new step toward glaucoma treatment-is mentioned briefly at the end of the article...
  66. doi request reprint Incidence of appropriate cardioverter-defibrillator shocks and mortality in patients with heart failure treated with combined cardiac resynchronization plus implantable cardioverter-defibrillator therapy versus implantable cardioverter-defibrillator thera
    Harit Desai
    Department of Medicine, Cardiology Division, New York Medical College, Valhalla, NY 10595, USA
    J Cardiovasc Pharmacol Ther 15:37-40. 2010
    ..Use of CRT, statins, and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers reduced mortality and hypertension, diabetes, and older age increased mortality...
  67. ncbi request reprint Cardiovascular complications of eating disorders
    Deena Casiero
    Department of Medicine, Montefiore Medical Center, Bronx, New York, USA
    Cardiol Rev 14:227-31. 2006
    ..Patients will require close monitoring and slower refeedings to minimize the risk of these complications...
  68. ncbi request reprint Transmyocardial revascularization: defining its role
    Ross F Goldberg
    Department of Surgery, St Vincent s Medical Center, New York, NY, USA
    Cardiol Rev 13:52-5. 2005
    ..Additional studies need to be done with TMR to assess whether it is a useful treatment or an addition to the list of placebo therapies initially thought to have been of benefit in the therapy for angina pectoris...
  69. ncbi request reprint Adrenomedullin: a vasoactive and natriuretic peptide with therapeutic potential
    J J Lah
    Department of Medicine, New York Medical College, Valhalla, NY 10595, USA
    Heart Dis 2:259-65. 2000
    ..In addition, adrenomedullin has actions in the brain, lungs, and kidneys to regulate regional hemodynamics. With these activities defined, recent studies have suggested a potential therapeutic role for adrenomedullin...
  70. pmc Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for prevention of stroke
    S Warshafsky
    Section of General Internal Medicine, Department of Medicine, New York Medical College, Valhalla, NY 10595, USA
    J Gen Intern Med 14:763-74. 1999
    ..Data from 13 placebo-controlled trials suggest that on average one stroke is prevented for every 143 patients treated with statins over a 4-year period...
  71. ncbi request reprint Innovative pharmacologic approaches to cardiopulmonary resuscitation
    T Kelsch
    Department of Medicine, New York Medical College, Westchester County Medical Center, Valhalla, New York, USA
    Heart Dis 3:46-54. 2001
    ..e., theophylline) for bradyasystolic rhythms. More innovative approaches include the use of thyroid hormone and endothelin...
  72. ncbi request reprint Thyroid hormone and cardiovascular disease
    M Gomberg-Maitland
    Department of Medicine, New York Hospital Cornell Medical Center, NY, USA
    Am Heart J 135:187-96. 1998
    ..At present there is no evidence suggesting a favorable treatment outcome using thyroid hormone supplementation for any systemic condition except in those patients with documented hypothyroidism...
  73. doi request reprint Relation of baseline plasma ADMA levels to cardiovascular morbidity and mortality at two years in men with diabetes mellitus referred for coronary angiography
    Erdal Cavusoglu
    Division of Cardiology, Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY, United States
    Atherosclerosis 210:226-31. 2010
    ..High baseline plasma levels of ADMA in patients with DM have been shown to predict diabetes related complications. However, there are limited data on the prognostic significance of baseline ADMA levels in patients with established DM...
  74. doi request reprint Prevalence of appropriate cardioverter-defibrillator shocks in 1038 consecutive patients with implantable cardioverter-defibrillators
    Adam Kruger
    Department of Medicine, Cardiology Division, New York Medical College, Valhalla, NY 10595, USA
    Am J Ther 16:323-5. 2009
    ..In conclusion, patients having implantable cardioverter-defibrillators should also be treated with beta-adrenergic blockers to reduce the frequency of appropriate shocks...
  75. doi request reprint Endothelin as a clinical target in the treatment of systemic hypertension
    Vinoy S Prasad
    Department of Medicine, UCLA School of Medicine Harbor UCLA Medical Center, Torrance, California, USA
    Cardiol Rev 17:181-91. 2009
    ....
  76. doi request reprint Therapeutic angiogenesis: a new treatment approach for ischemic heart disease--part I
    Anna Ahn
    Department of Medicine, Long Island Jewish Medical Center Albert Einstein College of Medicine, New Hyde Park, New York, USA
    Cardiol Rev 16:163-71. 2008
    ..The results of clinical trials with growth factor infusions and gene therapy techniques to enhance growth factor production have shown some promise, but therapeutic angiogenesis remains at an early stage of development...
  77. doi request reprint Cardiovascular considerations in patients undergoing gastrointestinal endoscopy
    Chaim Ross
    Department of Medicine, Division of Cardiology, New York Medical College Westchester Medical Center, Valhalla, New York 10595, USA
    Cardiol Rev 16:76-81. 2008
    ..In this article, treatment recommendations are included for those patients undergoing endoscopy who are receiving anticoagulation and for those who are at risk for bacterial endocarditis...
  78. ncbi request reprint Role of infection in atherosclerosis and coronary artery disease: a new therapeutic target?
    William H Frishman
    Department of Medicine and Pharmacology New York Medical College Westchester Medical Center, Valhalla, New York, USA
    Cardiol Rev 10:199-210. 2002
    ..In high-risk patients, the results of these most recent studies have not revealed any benefit of treatment...
  79. ncbi request reprint Use of pharmaceuticals in noninvasive cardiovascular diagnosis
    Jay S Meisner
    Department of Medicine, Divisions of Cardiology, Albert Einstein College of Medicine Montefiore Medical Center, Bronx, New York, USA
    Heart Dis 4:315-30. 2002
    ..The last group reviewed includes echocardiographic contrast agents that, in this investigative setting, are employed to enhance detection of segmental wall motion when used with agents from groups 2 and 3...
  80. ncbi request reprint Diabetes mellitus and coronary artery disease: therapeutic considerations
    Joydeep Ghosh
    Division of Cardiology, Department of Medicine, Westchester Medical Center New York Medical College, Valhalla, New York 10595, USA
    Heart Dis 5:119-28. 2003
    ....
  81. ncbi request reprint Cardiology patient page. Beta-adrenergic blockers
    William H Frishman
    Department of Medicine, New York Medical College, Westchester Medical Center, Munger Pavilion 263, Valhalla, NY 10595, USA
    Circulation 107:e117-9. 2003
  82. ncbi request reprint Cardiovascular effects of psychotropic drugs
    Robert E Feinstein
    Psychiatry, New York Medical College, Valhalla, NY, USA
    Curr Probl Cardiol 27:190-240. 2002
  83. ncbi request reprint The cardiac ryanodine receptor (RyR2) and its role in heart disease
    Ying Taur
    Department of Medicine, Long Island Jewish Medical Center Albert Einstein College of Medicine, Manhasset, New York, USA
    Cardiol Rev 13:142-6. 2005
    ..As our understanding of this receptor and its modulators deepens, the possibility of clinical application draws near...
  84. ncbi request reprint Nonpharmacologic approaches for the treatment of hyperlipidemia
    Tanaz Kermani
    Department of Medicine, Mayo Clinic Mayo Clinic School of Medicine, Rochester, Minnesota, USA
    Cardiol Rev 13:247-55. 2005
    ....
  85. ncbi request reprint Nutriceuticals in cardiovascular disease: psyllium
    Lavanya Petchetti
    Department of Medicine, Mt Vernon Hospital, Mt Vernon, New York, USA
    Cardiol Rev 15:116-22. 2007
    ..In combination with other cholesterol-lowering drugs, such as statins, psyllium provides an added benefit on cholesterol lowering, and is well tolerated and cost-effective...
  86. ncbi request reprint Cardiovascular pharmacotherapeutic considerations during pregnancy and lactation
    Shadi A Qasqas
    Departments of Medicine, Washington University School of Medicine Barnes Jewish Hospital, St Louis, Missouri, USA
    Cardiol Rev 12:240-61. 2004
    ..Table 2 summarizes the recommendations regarding the use of cardiovascular drugs during pregnancy and lactation...
  87. ncbi request reprint Comprehensive management of hypertensive emergencies and urgencies
    George A Mansoor
    Section of Hypertension and Vascular Diseases, University of Connecticut Health Center, Farmington, Connecticut 06030 3940, USA
    Heart Dis 4:358-71. 2002
    ..Most patients respond to drug therapy, but problems may arise related to a rapid normalization of blood pressure...
  88. ncbi request reprint Cyclooxygenase inhibition in patients with coronary artery disease
    William H Frishman
    J Am Coll Cardiol 43:532-3. 2004
  89. ncbi request reprint Pharmacokinetics of propranolol after single and multiple dosing with sustained release propranolol or propranolol CR (innopran XL) , a new chronotherapeutic formulation
    Domenic Sica
    Section of Clinical Pharmacology and Hypertension, Division of Nephrology, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA 23298 0160, USA
    Heart Dis 5:176-81. 2003
    ..Bioavailability was similar for both formulations of propranolol. Propranolol CR exhibited appropriate pharmacokinetics for a chronotherapeutic approach to the treatment of hypertension...
  90. ncbi request reprint Protein kinase C in cardiac disease and as a potential therapeutic target
    Stephen Murphy
    Department of Internal Medicine, University of Colorado School of Medicine, Denver, CO, USA
    Cardiol Rev 13:3-12. 2005
    ....
  91. ncbi request reprint Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren
    Reza Sepehrdad
    Department of Internal Medicine, UC Davis Medical Center, Sacramento, California, USA
    Cardiol Rev 15:242-56. 2007
    ....
  92. ncbi request reprint Drug therapy of neurovascular disease
    Jesse Weinberger
    Department of Neurology, Mt Sinai Medical Center, New York, New York, USA
    Cardiol Rev 11:122-46. 2003
    ..Innovative therapies are now available for the treatment of migraine and vascular dementia. Primary prevention of stroke remains the optimal therapeutic strategy and includes treatment of systemic hypertension and hypercholesterolemia...
  93. ncbi request reprint Adverse dermatologic effects of cardiovascular drug therapy: part I
    William H Frishman
    Department of Medicine, New York Medical College, Valhalla, New York, USA
    Cardiol Rev 10:230-46. 2002
    ..For example, cardiovascular drugs can induce a vast array of adverse dermatologic responses. This article reviews the various cutaneous reaction patterns that can occur as a result of treatment with Class I and II antiarrhythmic agents...
  94. ncbi request reprint Humor and the cardiovascular system
    Ara Sahakian
    Department of Medicine, Cedars Sinai Medical Center, Los Angeles, Calif, USA
    Altern Ther Health Med 13:56-8. 2007
  95. doi request reprint Investigational antiplatelet drugs for the treatment and prevention of coronary artery disease
    Joshua F Zeidner
    Department of Medicine, Johns Hopkins School of Medicine Johns Hopkins Hospital, Baltimore, Maryland, USA
    Cardiol Rev 16:250-9. 2008
    ....
  96. ncbi request reprint Gender, ethnicity and genetics in cardiovascular disease: part 1: Basic principles
    Benjamin M Schaefer
    Department of Medicine, Jacobi Medical Center, Brooklyn, NY, USA
    Heart Dis 5:129-43. 2003
    ..In particular, genetic polymorphisms of cardiovascular candidate genes and drug metabolism are described. The pharmacodynamic and pharmacokinetic variations among genders and ethnicities are summarized...
  97. ncbi request reprint Sirolimus-eluting coronary stents: novel devices for the management of coronary artery disease
    Angela Cheng-Lai
    Department of Pharmacy, Montefiore Medical Center Jack D Weiler Hospital of the Albert Einstein College of Medicine, Bronx, New York, USA
    Am J Ther 11:218-28. 2004
    ..This review article focuses on the pharmacology as well as clinical studies of the sirolimus-eluting stent...
  98. ncbi request reprint Use of diuretics in the treatment of heart failure in the elderly
    Domenic A Sica
    Division of Nephrology, Virginia Commonwealth University Health System, Richmond, VA, USA
    Clin Geriatr Med 23:107-21. 2007
    ....
  99. ncbi request reprint Chymase: a new pharmacologic target in cardiovascular disease
    Christopher Bacani
    Department of Medicine, Mayo Clinic, Jacksonville, Florida, USA
    Cardiol Rev 14:187-93. 2006
    ..Pharmacologic strategies that serve to inhibit chymase function may prove to be useful in the setting of vascular injury...